ArriVent BioPharma (AVBP) Long-Term Investments (2024 - 2025)

ArriVent BioPharma (AVBP) reported Long-Term Investments of $5.1 million for Q3 2025, down 72.82% sequentially from $18.8 million in Q2 2025.

ArriVent BioPharma (AVBP) Long-Term Investments (2024 - 2025) Analysis & Trends

ArriVent BioPharma (AVBP) has 2 years of Long-Term Investments data on file, last reported at $5.1 million in Q3 2025.

For the quarter ending Q3 2025, Long-Term Investments changed N/A year-over-year to $5.1 million; the trailing twelve-month figure through Sep 2025 stood at $5.1 million (changed N/A YoY), and the FY2024 full-year result was $47.7 million, changed N/A from the prior year.
Long-Term Investments declined to $5.1 million in Q3 2025, from $18.8 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $47.7 million in Q4 2024 to a low of $5.1 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	ArriVent BioPharma	1.42 Bn	1.42 Bn	-	-

Download Data